StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report released on Saturday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Trading Up 7.7 %
NASDAQ:EVOK opened at $0.51 on Friday. Evoke Pharma has a 12-month low of $0.40 and a 12-month high of $1.77. The firm has a market cap of $4.37 million, a PE ratio of -0.28 and a beta of 0.38. The stock has a fifty day moving average price of $0.49 and a 200 day moving average price of $0.64.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its quarterly earnings data on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter. Evoke Pharma had a negative net margin of 116.75% and a negative return on equity of 4,908.09%. The company had revenue of $1.74 million during the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Stories
- Five stocks we like better than Evoke Pharma
- Business Services Stocks Investing
- RXO Shares Surge Following New Acquisition Deal
- Investing in the High PE Growth Stocks
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Do ETFs Pay Dividends? What You Need to Know
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
